Photodynamic therapy (PDT) is a method that combines photosensitive drugs and laser activation to treat cancer. It has the advantages of minimally invasiveness, strong spatiotemporal controllability, small side effects, and low incidence of drug resistance. Traditional PDT uses light to excite a photosensitizer (PS) and transfer energy to oxygen to produce highly toxic reactive oxygen species (ROS) to induce tumor cell death. However, defects such as poor water solubility and strong oxygen dependence limit its anti-tumor efficacy.

In response to the limitations of traditional PS, Professor Huang Huaiyi of Sun Yat-sen University designed and synthesized a series of new metallic iridium photocatalysts with good biocompatibility and can be used for tumor treatment in hypoxic environments [1-3]. This type of photocatalyst has a high singlet oxygen quantum yield, shows a strong photocatalytic oxidation effect on NADPH, is not toxic to tumor cells and normal cells in the dark, and is toxic to tumors under light and normoxic or hypoxic conditions. Cells have strong growth inhibition capabilities. In addition, Associate Professor Huang Huaiyi also developed a dual-nuclear metal iridium photocatalyst [3][3]

Huang Huaiyi is a professor at Sun Yat-sen University, a doctoral supervisor, and a recipient of the Guangdong Provincial Outstanding Youth Fund. The main research direction is the molecular mechanism of tumor energy and material metabolism reprogramming, and the development of tumor photocatalytic treatment strategies. Using metal photocatalysts as light-activated chemical tools disrupts the electron transfer and material synthesis basis of tumor cells, achieving spatiotemporal regulation of tumor metabolism reprogramming, and provides a new strategy for the research of light-activated metal anti-tumor drugs. Relevant research results have been published as the first or corresponding author in more than 60 papers in authoritative academic journals at home and abroad such as Nat. Chem., Angew. Chem. Int. Ed., Sci. China Chem., Coord. Chem. Rev., and Biomaterials. , obtained 11 Chinese invention patent authorizations for metal drugs.

Bailingwei exclusively supplies the new metal iridium photocatalyst developed by Associate Professor Huang Huaiyi of Sun Yat-sen University. The product advantages are as follows:
It has excellent photocatalytic reaction performance and can be used in research fields such as tumor photocatalytic treatment research, photocatalytic organic synthesis reactions, photocatalytic hydrogen production, and cell imaging;
It has a unique excited-state redox potential and can be used as an excited-state oxidant or reducing agent for photocatalytic reactions;
It has high photostability, easy storage, safe operation, wide application range and efficient reaction.

Recommended products